natgillin/translations-raw huggingface dataset:
Withdraw 0.2 ml of the reconstituted vaccine into the syringe provided with the vaccine (see Figure 1) and connect the applicator to the needle (see Figure 2).
S priloženo brizgo odvzemite 0,2 ml rekonstituiranega cepiva (glejte sliko 1) in na iglo namestite aplikator (glejte sliko 2).
Withdraw 0.9 ml of a 0.9 ml labelled vial of atosiban 6.75 mg/0.9 ml, solution for injection and administer slowly as an intravenous bolus dose over one minute, under adequate medical supervision in an obstetric unit.
Izvlecite 0,9 ml iz 0,9-ml označene viale atosibana 6,75 mg/0,9 ml raztopina za injiciranje in aplicirajte počasi v intravenskem bolusu eno minuto pod ustreznim zdravniškim nadzorom na porodnem oddelku.
Withdraw 1.8 ml of the supplied diluent.
Odvzemite 1,8 ml vehikla iz priložene viale.
Withdraw 1.9 ml of Myocet liposomes.
Vzemite 1,9 ml liposomov Myocet.
Withdraw 2.1 ml of water for injections into a sterile syringe.
Sterilno brizgo napolnite z 2,1 ml vode za injekcije.
Withdraw 20 ml sodium chloride solution for injection (0.9%), (not provided in the package), and inject into each Myocet doxorubicin HCl, intended for preparation.
Vzemite 20 ml natrijevega klorida 9 mg/ml (0,9 %) raztopine za injiciranje (ni na voljo v kompletu) in jo injicirajte v vsako od vial Myocet doksorubicinijev klorida, namenjeno pripravi.
Withdraw 40 mL from each of the three reconstituted vials and add to D5W intravenous bag to bring the bag volume to 1,000 mL.
Iz vsake od treh rekonstituiranih vial izvlecite 40 ml in vsebino vnesite v vrečo za intravensko infuzijo D5W, da dobite volumen vreče 1.000 ml.
Withdraw 5 ml (300 mg) of reconstituted Entyvio using a syringe with a 21-25 gauge needle.
Izvlecite 5 ml (300 mg) rekonstituirane raztopine zdravila Entyvio v injekcijsko brizgo s pomočjo injekcijske igle, velikosti 21-25 G.
Withdraw 5 mL from one reconstituted vial and further dilute by adding to a 250 mL sodium chloride 9 mg/mL (0.9%) solution for injection or glucose (5%) solution for injection.
Izvlecite 5 ml iz ene rekonstituirane viale in naprej razredčite z dodajanjem 250 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injekcije ali raztopine glukoze (5 %) za injekcije.
Withdraw 5 ml from the vial, and further dilute in a total volume of 5% 50 ml of glucose solution for injection, or sodium chloride 9 mg/ml (0.9%) solution for injection to give a final bivalirudin concentration of 5 mg/ml.
Nato vzemite 5 ml iz viale in dodatno razredčite na celotni volumen 50 ml s5 % raztopino za injiciranje ali o 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje, da je končna koncentracija bivalirudina 5 mg/ml.
Withdraw 5 ml from the vial, and further dilute in a total volume of 50 ml of glucose 5% solution for injection, or sodium chloride 9 mg/ml (0.9%) solution for injection to give a final bivalirudin concentration of 5 mg/ml.
Nato vzemite 5 ml iz viale in dodatno razredčite na skupni volumen 50 ml s 5 % raztopino glukoze za injiciranje ali 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje, da je končna koncentracija bivalirudina 5 mg/ml.
withdraw 5 ml of ofatumumab from each of 3 vials and inject into the 1,000 ml bag; do not shake, mix diluted solution by gentle inversion.
potegnite 5 ml ofatumumaba iz vsake od 3 vial in ga injicirajte v 1.000-ml vrečko; ne stresajte, ampak razredčeno raztopino premešajte s previdnim obračanjem.
withdraw 50 ml of ofatumumab from each of 2 vials and inject into the 1,000 ml bag; do not shake, mix diluted solution by gentle inversion.
potegnite 50 ml ofatumumaba iz vsake od 2 vial in ga injicirajte v 1.000-ml vrečko; ne stresajte, ampak razredčeno raztopino premešajte s previdnim obračanjem.
withdraw 50 ml of ofatumumab from the vial and inject into the 1,000 ml bag; do not shake, mix diluted solution by gentle inversion.
potegnite 50 ml ofatumumaba iz viale in ga injicirajte v 1.000-ml vrečko; ne stresajte, ampak razredčeno raztopino premešajte s previdnim obračanjem.
Withdraw a portion of the diluted vaccine into the syringe to rinse ampoule.
Izvlecite del razredčenega cepiva v brizgo, da izperete ampulo.
Withdraw a portion of the solvent into the syringe to rinse the ampoule.
Potegnite del topila v brizgo, da sperete ampulo.
Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/ml (0.9%) solution for injection from a 100 ml infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.
V aseptičnih pogojih iz 100-ml vrečke za infundiranje izvlecite toliko sterilne, apirogene 0,9 % (9 mg/ml) raztopine natrijevega klorida za injiciranje, kot je potrebni volumen koncentrata zdravila RoActemra za bolnikov odmerek.
Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/ml (0.9%) solution for injection from a 100 ml infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.
V aseptičnih pogojih iz 100-ml vrečke za infundiranje izvlecite toliko sterilne, apirogene 0,9-% (9 mg/ml) raztopine natrijevega klorida za injiciranje, kot je potrebni volumen koncentrata zdravila RoActemra za bolnikov odmerek.
Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/ml (0.9%) solution for injection from a 50 ml infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.
V aseptičnih pogojih iz 50-ml vrečke za infundiranje izvlecite toliko sterilne, apirogene 0,9 % (9 mg/ml) raztopine natrijevega klorida za injiciranje, kot je potrebni volumen koncentrata zdravila RoActemra za bolnikov odmerek.
Withdraw a volume of sterile, non-pyrogenic sodium chloride 9 mg/ml (0.9%) solution for injection from a 50 ml infusion bag, equal to the volume of RoActemra concentrate required for the patients dose, under aseptic conditions.
V aseptičnih pogojih iz 50-ml vrečke za infundiranje izvlecite toliko sterilne, apirogene 0,9-% (9 mg/ml) raztopine natrijevega klorida za injiciranje, kot je potrebni volumen koncentrata zdravila RoActemra za bolnikov odmerek.
Withdraw air to equalise the pressure in the vial by pulling back slightly on the plunger.
Za izenačitev tlaka v viali spustite zrak, tako da bat rahlo potegnete nazaj.
Withdraw all of the contents from the mixing cup into the oral dispenser (~5 mL)
v odmernik izvlecite celotno vsebino iz čaše za mešanje (~5 ml)
Withdraw an appropriate volume of the reconstituted solution (4 mg/5 ml) as needed:
Odvzemite ustrezni volumen rekonstituirane raztopine (4 mg/5 ml), kot sledi:
withdraw and discard 100 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection withdraw 50 ml of ofatumumab from each of 2 x 1,000 mg vials and inject into the 1,000 ml bag
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 100 ml raztopine in jih zavrzite; potegnite 50 ml ofatumumaba iz vsake od 2-eh vial s 1.000 mg in ga injicirajte v 1.000-ml vrečko;
withdraw and discard 100 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection;
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 100 ml raztopine in jih zavrzite;
Withdraw and discard 120 mL from a 1,000 mL D5W intravenous bag.
Iz 1.000 ml vreče za intravensko infuzijo D5W izvlecite 120 ml tekočine in jo zavrzite.
withdraw and discard 15 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection withdraw 5 ml of ofatumumab from each of 3 x 100 mg vials and inject into the 1,000 ml bag
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 15 ml raztopine in jih zavrzite; potegnite 5 ml ofatumumaba iz vsake od 3-eh vial s 100 mg in ga injicirajte v 1.000-ml vrečko;
withdraw and discard 15 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection;
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 15 ml raztopine in jih zavrzite;
withdraw and discard 50 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection withdraw 50 ml of ofatumumab from the 1,000 mg vial and inject into the 1,000 ml bag
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 50 ml raztopine in jih zavrzite; potegnite 50 ml ofatumumaba iz viale s 1.000 mg in ga injicirajte v 1.000-ml vrečko;
withdraw and discard 50 ml from a 1,000 ml bag of sodium chloride 9 mg/ml (0.9%) solution for injection;
iz 1.000-ml vrečke 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje potegnite 50 ml raztopine in jih zavrzite;
Withdraw and discard a volume of sodium chloride 9 mg/ml (0.9%) solution for infusion from the infusion bag equal to the total volume of Aldurazyme to be added.
Iz vrečke za infuzijo odstranite in zavrzite količino 0,9% raztopine natrijevega klorida (9 mg/ml), ki je enaka količini zdravila Aldurazyme, ki ga boste dodali.
Withdraw patient
Prenehajte s to terapijo
Withdraw the 0.5 ml dose of vaccine from the single-dose vial using a sterile needle and syringe.
S sterilno iglo in injekcijsko brizgo iz enoodmerne viale izvlecite 0,5 ml odmerek cepiva.
Withdraw the 0.5 ml dose of vaccine from the vial using a sterile needle and syringe.
S sterilno iglo in injekcijsko brizgo iz enoodmerne viale izvlecite 0,5 ml odmerek cepiva.
Withdraw the appropriate volume of the reconstituted solution (4 mg/5 ml), as follows:
Odvzemite ustrezni volumen rekonstituirane raztopine (4 mg/5 ml), kot sledi:
Withdraw the correct dose of Strensiq into the syringe.
V injekcijsko brizgo izvlecite pravilni odmerek zdravila Strensiq.
Withdraw the entire content of the reconstituted vaccine from the vial into the same syringe and inject the entire volume.
Celotno vsebino povlecite v isto brizgo in injicirajte celotno količino.
Withdraw the entire content of the reconstituted vaccine usingthe same syringe.
Celotno vsebino viale z rekonstituiranim cepivom povlecite iz viale v isto injekcijsko brizgo.
Withdraw the entire contents of the reconstituted vaccine into a sterile syringe and administer the whole contents subcutaneously.
S sterilno brizgo odvzemite vso količino rekonstituiranega cepiva in cepivo vbrizgajte subkutano.
Withdraw the entire contents of the reconstituted vaccine into a sterile syringe and administer the whole contents subcutaneously.
S sterilno brizgo odvzemite vso količino rekonstituiranega cepiva in vse cepivo vbrizgajte subkutano.
Withdraw the entire contents of the reconstituted vaccine using the same syringe.
Celotno vsebino rekonstituiranega cepiva povlecite v isto injekcijsko brizgo.
Withdraw the entire contents of the vial.
V brizgo potegnite celotno vsebino viale.
Withdraw the entire volume of solvent into a syringe to be used for reconstitution and injection.
Za pripravo cepiva za injiciranje potegnite celoten volumen vehikla v brizgo.
Withdraw the entire volume.
Izvlecite celotni volumen raztopine.
Withdraw the exact amount of Rapamune oral solution as prescribed by your doctor by gently pulling out the plunger of the dosing syringe until the bottom of the black line of the plunger is level with the appropriate mark on the dosing syringe.
Potegnite ustrezno količino zdravila Rapamune peroralne raztopine, kot vam jo je predpisal zdravnik, tako da potegnete bat v odmerni brizgi počasi ven, dokler spodnji, črni del bata ne doseže želene oznake na odmerni brizgi.
Withdraw the full contents of the recombinant human hyaluronidase into the syringe.
Vso vsebino rekombinantne humane hialuronidaze povlecite v brizgo.
Withdraw the necessary amount of DARZALEX solution and dilute to the appropriate volume by adding to an infusion bag/container containing 0.9% Sodium Chloride (see section 4.2).
Izračunani volumen DARZALEX koncentrata za raztopino za infundiranje razredčite do ustreznega volumna tako, da ga dodate v infuzijsko vrečko/vsebnik z 0,9-odstotno raztopino natrijevega klorida (glejte poglavje 4.2).
Withdraw the needle and shake the vial to give a clear solution.
Izvlecite iglo in pretresite vialo, da bo nastala bistra raztopina.
Withdraw the needle from the injection site and activate the safety guard (as shown in Step 8).
Izvlecite iglo z mesta injiciranja in aktivirajte varnostni ščitnik (kot je prikazano pri
Withdraw the needle from the skin, then release the pressure on the push–button.
Izvlecite iglo iz kože ter nato spustite potisni gumb.
Withdraw the needle quickly and apply pressure over the injection site with a dry, sterile pad.
Iglo hitro izvlecite, na mesto injiciranja pa pritisnite suho sterilno blazinico.
Withdraw the reconstituted vaccine concentrate from the vial(s) and inject it back into the Nobivac Myxo-RHD solvent vial.
Izvlecite rekonstituirani koncentrat cepiva iz vial/e in ga injicirajte nazaj v vialo z Nobivac Myxo- RHD vehiklom.
Withdraw the required amount of concentrate-diluent mixture (which contains temsirolimus 10 mg/ml) from the vial; i.e., 2.5 ml for a temsirolimus dose of 25 mg.
Odvzemite potrebno količino zmesi koncentrata in vehikla (ki vsebuje 10 mg temsirolimusa na ml) iz viale; tj., 2,5 ml za 25-miligramski odmerek temsirolimusa.
Withdraw the required amount of Soliris from the vial(s) using a sterile syringe.
S sterilno brizgo odvzemite zahtevano količino zdravila Soliris iz viale (vial).
Withdraw the required amount of the temsirolimus-diluent mixture (10 mg/ml) and then inject rapidly into sodium chloride 9 mg/ml (0.9%) solution for injection.
Odvzemite potrebno količino razredčene raztopine temsirolimusa (10 mg/ml) in jo nato hitro injicirajte v raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
Withdraw the required dose volume
Odvzemite potreben volumen odmerka.
Withdraw the required volume of Nivolumab BMS concentrate using an appropriate sterile syringe.
Potrebni volumen koncentrata zdravila Nivolumab BMS izvlecite v ustrezno sterilno injekcijsko brizgo.
Withdraw the required volume of the radiolabelled product into the required number of syringes.
Potrebno prostornino radiooznačenega zdravila izvlecite v potrebno število injekcijskih brizg.
Withdraw the required volume up to 2 mL (50 mg) of KEYTRUDA and transfer into an intravenous bag containing sodium chloride 9 mg/mL (0.9%) or glucose 50 mg/mL (5%) to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL.
Potrebno količino do 2 ml (50 mg) zdravila KEYTRUDA povlecite iz viale in jo prenesite v intravensko vrečko, ki vsebuje natrijev klorid 9 mg/ml (0,9 %) ali glukozo 50 mg/ml (5 %), da pripravite razredčeno raztopino s končno koncentracijo od 1 do 10 mg/ml.
Withdraw the required volume up to 4 mL (100 mg) of concentrate and transfer into an intravenous bag containing sodium chloride 9 mg/mL (0.9%) or glucose 50 mg/mL (5%) to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL.
Potrebno količino do 4 ml (100 mg) koncentrata povlecite iz viale in jo prenesite v intravensko vrečko, ki vsebuje natrijev klorid 9 mg/ml (0,9 %) ali glukozo 50 mg/ml (5 %), da pripravite razredčeno raztopino s končno koncentracijo od 1 do 10 mg/ml.
Withdraw the suspension using a syringe and needle and add it to an infusion bag containing 100 ml of either sodium chloride 9 mg/ml (0.9%) solution for injection or dextrose 50 mg/ml (5%) solution for injection and mix to complete dissolution.
100 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 100 ml 50 mg/ml (5 %) raztopine dekstroze za injiciranje in zmešajte, da se zaključi proces raztapljanja.
Withdraw the suspension using a syringe and needle and add it to an infusion bag containing 100 ml of either sodium chloride 9 mg/ml (0.9%) solution for injection or dextrose 50 mg/ml (5%) solution for injection and mix to complete dissolution.
Suspenzijo potegnite v brizgo z iglo in jo injicirajte v infuzijsko vrečko, ki vsebuje bodisi 100 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali pa 100 ml 50 mg/ml (5 %) raztopine dekstroze za injiciranje in zmešajte, da se zaključi proces raztapljanja.
Withdraw the syringe from the vial.
Iglo injekcijske brizge izvlecite iz viale.
Withdraw with a sterile needle and syringe, 2 ml of an acceptable solvent and insert the needle through the central portion of the rubber stopper transferring the solvent into the parecoxib 40 mg vial.
S sterilno iglo in brizgo izvlecite 2 ml dovoljenega vehikla; zabodite iglo skozi osrednji del gumijastega zamaška in prenesite vehikel v 40-mg vialo parekoksiba.
Withdraw, with a sterile needle and syringe, 2 ml of an acceptable solvent and insert the needle through the central portion of the rubber stopper transferring the solvent into the 40 mg vial.
S sterilno iglo in brizgo izvlecite 2 ml dovoljenega vehikla; zabodite iglo skozi osrednji del gumijastega zamaška in prenesite vehikel v 40 mg vialo.
Withdrawal
Karenca
Withdrawal
Odtegnitev zdravila Zonegran
Withdrawal
Prekinitev zdravljenja
Withdrawal
Prenehanje zdravljenja
Withdrawal due to nausea or vomiting each occurred in < 1 % for prolong-release exenatide treated patients and 1 % for immediate-release exenatide treated patients.
Prekinitev zaradi navzee ali bruhanja je bila pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, < 1 %, in pri bolnikih, ki so se zdravili z eksenatidom v obliki s takojšnim sproščanjem, 1 %.
Withdrawal due to nausea or vomiting each occurred in < 1 % for prolonged-release exenatide treated patients and 1 % for immediate-release exenatide treated patients.
Prekinitev zaradi navzee ali bruhanja je bila pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, < 1 %, in pri bolnikih, ki so se zdravili z eksenatidom v obliki s takojšnim sproščanjem, 1 %.
Withdrawal effects are not expected when stopping Sialanar.
Prenehanje dajanja zdravila Sialanar ne bi smelo imeti neželenih učinkov.
Withdrawal of Betaferon should be considered if the levels significantly increase or if they are associated with clinical symptoms such as jaundice.
Če se vrednosti transaminaz pomembno povečajo ali če jih spremljajo klinični simptomi zlatenice, je treba razmisliti o prekinitvi zdravljenja z zdravilom Betaferon.
Withdrawal of concomitant anti-epileptic medicinal products
Ukinitev sočasno uporabljenih antiepileptičnih zdravil
Withdrawal of concomitant anti-epileptic medicinal products
Ukinitev sočasnouporabljenih antiepileptičnih zdravil
Withdrawal of concomitant antiepileptic medicinal products
Ukinitev sočasno uporabljenih antiepileptičnih zdravil
Withdrawal of concomitant CNSdepressant medicinal products should also be considered as they may contribute to the reduced level of arousal.
Prav tako je potrebno razmisliti o ukinitvi sočasne uporabe zdravil z zaviralnim učinkom na CŽS, ker lahko pripomorejo k zmanjšani stopnji budnosti.
Withdrawal of INVEGA may be needed
Morda bo potrebno prekiniti zdravljenje z zdravilom INVEGA.
Withdrawal period
EMEA številka
Withdrawal period
emodepsida
WITHDRAWAL PERIOD
KARENCA
WITHDRAWAL PERIOD
KARENCA Goveda:
Withdrawal period
Karenca(e)
Withdrawal period
Steklenička
WITHDRAWAL PERIOD
ŠTEVILKA SERIJE
Withdrawal period - Zero days
Karenca - nič dni.
Withdrawal period - Zero days
Karenca – nič dni
Withdrawal period -Zero days
Karenca: nič dni
Withdrawal period : Meat and offal: 26 days
Meso in organi: 26 dni
Withdrawal period(s)
Karenca
Withdrawal period(s)
Karenca(e)
Withdrawal period(s) Cattle:
Karenca Goveda:
Withdrawal period(s) Cattle:
Karence Govedo:
Withdrawal period:
Karenca
Withdrawal period: 0 days
Karenca: nič dni
Withdrawal period: 7 days.
Karenca: 7 dni.
Withdrawal period: Cattle - meat and offal 46 days
Govedo-meso in organi 46 dni.
Withdrawal period: Cattle - meat and offal 46 days
Karenca: Govedo-meso in organi 46 dni
Withdrawal period: Meat and offal 46 days
Karenca: Meso in organi 46 dni
Withdrawal period: Meat and offal: 1 day.
Meso in organi: 1 dan
Withdrawal period: Meat and offal: 1 day.
Meso in organi: 1 dan.
Withdrawal period: Meat and offal: 10 days.
Karenca: meso in organi: 10 dni.
Withdrawal period: Meat and offal: 13 days.
Meso in organi: 13 dni.
Withdrawal period: Meat and offal: 13 days.
Meso in organi:13 dni.
Withdrawal period: Meat and offal: 2 days.
Meso in organi: 2 dni
Withdrawal period: Meat and offal: 2 days.
Meso in organi: 2 dni.
Withdrawal period: Meat and offal: 22 days.
Meso in organi: 22 dni.
Withdrawal period: Meat and offal: 23 days
Meso in organi: 23 dni Mleko:
Withdrawal period: Meat and offal: 26 days
Meso in organi: 26 dni
Withdrawal period: Meat and offal: 26 days.
Karenca: meso in organi: 26 dni
Withdrawal period: Meat and offal: 3 days.
Meso in organi: 3 dni
Withdrawal period: Meat and offal: 3 days.
Meso in organi: 3 dni.
Withdrawal period: Meat and offal: 47 days.
Karenca: Meso in organi: 47 dni
Withdrawal period: Meat and offal: 5 days.
Meso in organi: 5 dni.
Withdrawal period: Meat and offal: 71 days.
Meso in organi: 71 dni.
Withdrawal period: Meat and offal: 9 days
Meso in organi: 9 dni
Withdrawal period: Meat and offal: 9 days.
Meso in organi: 9 dni
Withdrawal period: Meat and offal: 9 days.
Meso in organi: 9 dni.
Withdrawal period: Meat and offal: Cattle: 22 days.
Meso in organi: Govedo: 22 dni.
Withdrawal period: Meat and offal: Cattle: 64 days.
Karenca: Meso in organi: Govedo: 64 dni.
Withdrawal period: Pigs:
Karenca: Prašiči:
Withdrawal period: See box
Karenca: glej škatlo.
Withdrawal period: Zero days
Karenca: 0 dni.
Withdrawal period: zero days
Karenca: nič dni
Withdrawal period: zero days
Karenca: Nič dni.
Withdrawal period: zero days.
Karenca: 0 dni
Withdrawal period: Zero days.
Karenca: 0 dni.
Withdrawal period: zero days.
Karenca: Nič dni
Withdrawal period: zero days.
Karenca: nič dni.
WITHDRAWAL PERIODS
KARENCA
Withdrawal periods
Karenca(e)
Withdrawal periods - Meat and offal (chickens and turkeys): 24 hours.
Meso in organi (piščanci in purani): 24 ur
Withdrawal periods Cattle:
Karenca(e) Govedo:
Withdrawal Rate due to ISRs
Delež prenehanja zdravljenja zaradi lokalnih interakcij na mestu injiciranja
Withdrawal seizures
Epileptični napadi ob odtegnitvi
withdrawal symptoms in newborn babies in case of exposure during pregnancy,
odtegnitveni simptomi pri novorojenčkih v primeru izpostavljenosti zdravilu v času nosečnosti,
Withdrawal symptoms may be precipitated through the administration of substances with opioid antagonist activity, e.g. naloxone, or mixed agonist/antagonist analgesic (e.g. pentazocine, butorphanol, buprenorphine, nalbuphine).
Odtegnitvene simptome lahko povzroči uporaba snovi, ki delujejo kot antagonisti opioidov, npr. nalokson, ali mešani analgetiki agonisti/antagonisti (npr. pentazocin, butorfanol, buprenorfin, nalbufin).
Withdrawal syndrome*
odtegnitveni sindrom
Withdrawal Volume
1500 mg
Withdrawal Volume
Odvzeti volumen
Withdrawals
Prenehanja uporabe
Withdrawing the right volume of your medicine with the help of the syringe markings
Odmerjanje ustrezne prostornine zdravila s pomočjo oznak na brizgi
Withdrawing the solution from the vial Attaching the applicator tip (see Figure 3):
Jemanje raztopine iz viale Pritrjevanje aplikacijskega nastavka (glejte sliko 3):
Withhold 1 or 2 doses
Zadržite 1 ali 2 odmerka
Withhold administration of cinacalcet until serum calcium levels reach 8.0 mg/dl (2.0 mmol/l) and/or symptoms of hypocalcaemia have resolved.
Odložite uporabo cinakalceta, dokler koncentracija kalcija v serumu ne doseže 8,0 mg/dl (2,0 mmol/l) in/ali dokler se ne rešijo simptomi hipokalciemije.
Withhold administration of Mimpara until serum calcium levels reach 8.0 mg/dl (2.0 mmol/l) and/or symptoms of hypocalcaemia have resolved.
Odložite uporabo zdravila Mimpara, dokler koncentracija kalcija v serumu ne doseže 8,0 mg/dl (2,0 mmol/l) in/ali dokler se ne rešijo simptomi hipokalciemije.
Withhold Bortezomib Accord treatment until symptoms of toxicity have resolved.
prekinite zdravljenje z zdravilom Bortezomib Accord, dokler ne minejo znaki toksičnosti.
Withhold Bortezomib Hospira treatment until symptoms of toxicity have resolved.
prekinite zdravljenje z zdravilom Bortezomib Hospira, dokler ne minejo znaki toksičnosti.
Withhold Bortezomib SUN treatment until symptoms of toxicity have resolved.
prekinite zdravljenje z zdravilom Bortezomib SUN, dokler ne minejo znaki toksičnosti.